Skip to main content
Home > SciBX > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Table 3: Largest series A financing rounds for companies founded in 2013

    Cover Story: Europe's upwelling Table 3. Largest series A financing rounds for companies founded in 2013. Unlike in 2011 and 2012, European biotechs boasted some of the largest series A rounds last year. Table …

    Published on 2/20/2014
  • Europe's upwelling

    SciBX's third annual comprehensive analysis of public-private partnerships and early stage venture financing activity shows that Europe's PPP activity in 2013 surpassed that of the U.S. in dramatic fashion.

    Published on 2/20/2014
  • Table 2: Top public-private partnerships in 2013 by value

    Cover Story: Europe's upwelling Table 2. Top public-private partnerships in 2013 by value. Public-private partnerships (PPPs) that include grants, awards and/or other types of direct funding support from national …

    Published on 2/20/2014
  • Curb your fatty acids

    A UCSF team has uncovered a pathway for regulating absorption of fatty acids that yielded MFGE8 as a new obesity target. The team is working on inhibitors of the integrin ligand or its receptors for use in the …

    Published on 2/13/2014
  • Germinating MALT1

    AstraZeneca has teamed up with the Flanders Institute for Biotechnology and the Centre for Drug Design and Discovery to make a play for inhibitors of MALT1. The announcement caps five years of progress toward validating…

    Published on 2/6/2014
  • BBB-conquering antibodies

    Roche has developed an improved transferrin receptor-targeting strategy that dramatically increases delivery of biologics to the brain. The team showed proof of concept in mice and now needs to adapt the system for …

    Published on 1/30/2014
  • Regeneron revisits genomics

    Regeneron has opened a genetics center tasked with analyzing the genomes of at least 100,000 patients in the next 5 years. The company hopes the volume of data, diversity of the patient population and rapid validation …

    Published on 1/23/2014
  • Figure 1: Putting the brakes or gas on T cell function

    Cover Story: Putting on the brakes Figure 1. Putting the brakes or gas on T cell function. Inhibitory chimeric antigen receptors (iCARs) put the brakes on T cell function upon encountering off-target cells. The iCAR …

    Published on 1/16/2014
  • Putting on the brakes

    A group at Memorial Sloan-Kettering Cancer Center has developed T cells that express an inhibitory chimeric antigen receptor, or iCAR, in addition to a cancer-specific CAR to prevent healthy cells from activating T cell…

    Published on 1/16/2014
  • Box 1: Revving up T cells

    Cover Story: Putting on the brakes Box 1. Revving up T cells. Michel Sadelain, director of the Memorial Sloan Kettering Cancer Center's Center for Cell Engineering, previously teamed with researchers from the …

    Published on 1/16/2014
  • Light it up

    Poor tumor definition makes it hard to remove all malignant cells during cancer surgery. A Texas team has designed fluorescent nanoparticles that can light up tumors regardless of genotype or phenotype, potentially …

    Published on 1/9/2014
  • Figure 1: Ultra pH-sensitive (UPS) nanoprobes shed new light on tumors

    Cover Story: Light it up Figure 1. Ultra pH-sensitive (UPS) nanoprobes shed new light on tumors. The UPS nanoprobes stay 'off' at pH 7.4 in normal blood vasculature. After reaching tumors, the UPS nanoprobes are …

    Published on 1/9/2014
  • Oral nanoparticles

    A U.S. research team has developed targeted nanoparticles that could enable the oral delivery of biologics. Translation of the approach will require identifying a suitable therapeutic payload and fine-tuning the …

    Published on 12/19/2013
  • T cells go universal

    Scientists have engineered T cells that engage in antibody-dependent cellular cytotoxicity and enhance the antitumor potential of any immunotherapeutic antibody. The team plans to test the T cell and antibody …

    Published on 12/12/2013
  • Targeting fibrotic integrin

    An international team of researchers has shown that the myofibroblast-expressed integrin alpha(V) subunit drives fibrosis and that a small molecule integrin alpha(V) antagonist from Antegrin Therapeutics can attenuate …

    Published on 12/5/2013
  • Glucokinase alternative

    Compounds that directly activate glucokinase effectively reduce blood sugar in patients with diabetes but increase the risk of adverse hypoglycemic events. Now, researchers from Amgen have identified compounds that act …

    Published on 11/21/2013
  • Table 1: Glucokinase activators in clinical development

    Cover Story: Glucokinase alternative Table 1. Glucokinase activators in clinical development. Despite the discontinuation of some programs from large pharmas, including Merck & Co. Inc. (NYSE:MRK), Takeda …

    Published on 11/21/2013
  • Trends with benefits

    The FDA set up its adverse event database to capture the side effects of marketed drugs, but U.S. researchers have now exploited the resource to extract new information-beneficial combinations that reduce a drug's risk …

    Published on 11/14/2013
  • ALS antisense oligonucleotides

    Isis and three academic groups are developing antisense oligonucleotide therapeutics for the most common cause of ALS. The drugs target hexanucleotide repeat expansions in C9orf72 and mitigate neurotoxicity in vitro. …

    Published on 11/7/2013
  • Figure 1: Meditope-enabled mAbs

    Cover Story: Building meditope-enabled mAbs Figure 1. Meditope-enabled mAbs. As reported by Donaldson et al., the Fab framework of the chimeric anti-epidermal growth factor receptor (EGFR) mAb Erbitux cetuximab …

    Published on 10/31/2013
  • Building meditope-enabled mAbs

    Researchers at the Beckman Research Institute at City of Hope have provided proof of concept for adapting the functionality of mAbs by modifying them with engineered peptides called meditopes. The institute founded …

    Published on 10/31/2013
  • Figure 1: Drug-like chemical modifications to nucleic acids

    A platform for RNA Figure 1. Drug-like chemical modifications to nucleic acids. Nucleic acids are not drug-like molecules, and chemical modifications are required to improve their pharmacokinetic and other properties…

    Published on 10/24/2013
  • Figure 2: The RNAi pathway

    A platform for RNA Figure 2. The RNAi pathway. MicroRNAs are transcribed in the nucleus as precursor pri-miRNAs, which form hairpins that are processed to mature miRNAs by two RNase III enzymes, drosha and dicer. [a(…

    Published on 10/24/2013
  • Table 1: Oligonucleotide therapeutic companies

    A platform for RNA Table 1. Oligonucleotide therapeutic companies. Source: BCIQ: BioCentury Online Intelligence; company press releases and websites Company Modality Stage of lead compound Antisense Therapeutics …

    Published on 10/24/2013
  • Table 2: Recent deals

    A platform for RNA Table 2. Recent deals. Deals between Isis Pharmaceuticals Inc. and Biogen Idec Inc., and Moderna Therapeutics Inc. and AstraZeneca plc, highlight increasing investments in oligonucleotide-based …

    Published on 10/24/2013

< Previous   1  2  3  4  5  6  7  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993